We Offer Worldwide Shipping
Login Wishlist



  • Brand : BIOFRON

  • Catalogue Number : BN-B0388

  • Specification : 95%(HPLC)

  • CAS number : 20013-75-6

  • Formula : C15H16O

  • Molecular Weight : 212.29

  • PUBCHEM ID : 12314812

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method






Molecular Weight




Botanical Source

This product is isolated and purified from the herbs of Chloranthus sertusra

Structure Type



Standards;Natural Pytochemical;API




Naphtho[2,1-b]furan, 6,7-dihydro-1,5,8-trimethyl-/1,5,8-Trimethyl-6,7-dihydronaphtho[2,1-b]furan




1.1±0.1 g/cm3


Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

155.0±6.1 °C

Boiling Point

327.3±11.0 °C at 760 mmHg

Melting Point




InChl Key


WGK Germany


HS Code Reference


Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:20013-75-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.


72nd Congress of the Italian Society of Pediatrics


Marco Braghero,corresponding author1 Annamaria Staiano,corresponding author2 Eleonora Biasin,corresponding author3 Patrizia Matarazzo,4 Silvia Einaudi,3 Rosaria Manicone,3 Francesco Felicetti,5 Enrico Brignardello,5 Franca Fagioli,3 Elisabetta Bignamini,corresponding author6 Elena Nave,6 F. Callea,corresponding author7 C. Concato,7 E. Fiscarelli,7 S. Garrone,7 M.Rossi de Gasperis,7 Patrizia Calzi,corresponding author8 Grazia Marinelli,8 Roberto Besana,8 Carlo Caffarelli,corresponding author9 Antonio Di Peri,9 Irene Lapetina,9 Patrizia Cincinnati,corresponding author10 Rosalia Maria Da Riol,corresponding author11 Mario De Curtis,corresponding author12 Lucia Dito,12 Chiara Protano,12 Susanna Esposito,corresponding author13 Dante Ferrara,corresponding author14,15 Rossella Galiano,corresponding author16 Pasquale Novellino,16 Eric Heath Kossoff,corresponding author17 Andrzej Krzysztofiak,18 Elena Bozzola,18 Laura Lancella,18 Alessandra Marchesi,18 Alberto Villani,18 Paola Lago,corresponding author19 Elisabetta Garetti,20 Anna Pirelli,21 Paola Marchisio,22 Maria Santagati,23 Stefania Stefani,23 Susanna Esposito,22 Nicola Principi,22 Valeria d’Apolito,24 Luigi Memo,corresponding author25 Angelo Selicorni,26 Vito Leonardo Miniello,corresponding author27 Lucia Diaferio,27 Antonella Palmieri,corresponding author28 Luciana Parola,corresponding author29 Ettore Piro,corresponding author30 Claudio Romano,corresponding author31 Maria Ausilia Catena,31 Sabrina Cardile,31 Oliviero Sacco,32 Donata Girosi,32 Roberta Olcese,32 Mariangela Tosca,32 Giovanni Arturo Rossi,corresponding author32 Sergio Salerno,corresponding author33 Maria Chiara Terranova,33 Francesca Santamaria,corresponding author34 Angelo Selicorni,corresponding author35,36 Giorgia Mancano,35,36 Silvia Maitz,36 Virginia A. Stallings,corresponding author37,38 Chiara Berlolaso,39 Carolyn McAnlis,37 Joan I. Schall,37 Pasquale Striano,corresponding author40 Rita Tanas,corresponding author41 Giulia De Iaco,42 Maria Marsella,43 Guido Caggese,44 Paolo Toma,corresponding author45 Piero Valentini,corresponding author46 Danilo Buonsenso,47 David Pata,46 Manuela Ceccarelli,48 Elvira Verduci,corresponding author49 Marta Brambilla,49 Benedetta Mariani,49 Carlotta Lassandro,49 Alice Re Dionigi,49 Sara Vizzuso,49 Giuseppe Banderali,49 Gianvito Panzarino,50 Claudia Di Paolantonio,50 Alberto Verrotti,50 Alberto Villani,51 Elena Bozzola,51 Laura Cursi,51 Annalisa Grandin,51 Andrzej Krzysztofiak,51 Laura Lancella,51 Raffaele Virdis,corresponding author52,53,55 Patrizia Carletti,52,54 Giovanna Weber,corresponding author56 Silvana Caiulo,56 and Maria Cristina Vigone56

Publish date





A taxonomic treatment, phylogeny based on analysis of six DNA sequence markers (ITS, ndhA intron, rpl32-trnL, rps3, rps16 intron and rps16-trnK) and classification of Muhlenbergia for Peru is given. Seventeen species and one presumed hybrid are recognised. Muhlenbergiaromaschenkoisp. nov. is newly described from the Rio Huallaga Valley, northeast of Huanuco. The type of Podosemumangustatum [≡ Muhlenbergiaangustata] clearly aligns with what we had been referring to as the hybrid between this species and M.rigida. Therefore, we adopt the next available heterotypic name, Muhlenbergiacoerulea, for what we had been calling M.angustata and change the hybrid designation to M.coerulea × M.rigida. Lectotypes are designated for Epicampescoerulea Griseb., Muhlenbergiaaffinis Trin., Muhlenbergiaberlandieri Trin., Muhlenbergiabeyrichiana Kunth, Muhlenbergiaelegansvar.atroviolacea Kuntze, Muhlenbergiaelegansvar.subviridis Kuntze and Muhlenbergiaphragmitoides Griseb.


classification, ITS, lectotypification, Muhlenbergia , Peru, phylogeny, plastid DNA sequences, Poaceae , systematics, taxonomy


Revision of Muhlenbergia (Poaceae, Chloridoideae, Cynodonteae, Muhlenbergiinae) in Peru: classification, phylogeny, and a new species, M.romaschenkoi


Paul M. Peterson,corresponding author1 Isidoro Sanchez Vega,2 Konstantin Romaschenko,1 Diego Giraldo-CaNas,3 and Nancy F. Refulio Rodriguez4

Publish date





We conducted a randomized trial to evaluate whether melphalan-prednisone (MPH-P) treatment administered just after diagnosis improves survival of stage I multiple myeloma (MM). Between January 1987 and March 1993, 145 consecutive previously untreated patients with stage I MM were randomized between treatment with MPH-P (administered for 4 days every 6 weeks) just after diagnosis and treatment only at disease progression. Survival was not influenced by MPH-P treatment either administered just after diagnosis or at disease progression (64 vs 71 months respectively). Comparing the first with the second group the odds ratio of death is 1.17 (95% confidence interval 0.57-2.42;P = 0.64). Disease progression occurred within a year in about 50% of patients who were initially untreated. Response rate was similar in both groups, but duration of response was shorter in patients who were treated at disease progression (48 vs 79 months, P = 0.044). Patients actually treated at disease progression (34/70) survived shorter than those who had neither disease progression nor treatment (56 vs > 92 months;P = 0.005). Starting MPH-P just after diagnosis does not improve survival and response rate in stage I MM, with respect to deferring therapy until disease progression. However, patients with stage I MM randomized to have treatment delayed and who actually progressed and were treated had shorter survival than those with stable disease and no treatment. Biologic or other disease features could identify these subgroups of patients. © 2000 Cancer Research Campaign


multiple myeloma, stage I, early or delayed treatment, survival


Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study


A Riccardi,1 O Mora,1 C Tinelli,2 D Valentini,1 S Brugnatelli,1 R Spanedda,3 A De Paoli,4 L Barbarano,5 M Di Stasi,6 M Giordano,7 C Delfini,8 G Nicoletti,9 C Bergonzi,10 E Rinaldi,11 L Piccinini,12 E Ascari,1 and for the Co-operative Group of study and Treatment of Multiple Myeloma

Publish date

2000 Apr;

Description :

Empty ...